LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shared Science Publishers OG
2019-10-01
|
Series: | Cell Stress |
Subjects: | |
Online Access: | http://www.cell-stress.com/researcharticles/2019a-liao-cell-stress/ |